Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide

Pituitary

Volumn 15, Issue 4, 2012, Pages 518-525

  Couture, Elisabeth ^a   Bongard, Vanina ^a   Maiza, Jean Christophe ^a   Bennet, Antoine ^a   Caron, Philippe ^a  

^a CHU RANGUEIL   (France)

Author keywords

Acromegaly; Glucose status; IGF 1; Lanreotide; Somatostatin analog

Indexed keywords

ANGIOPEPTIN; AUTOGEL; GLUCOSE; GROWTH HORMONE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CONTROL; GLUCOSE STATUS; GROWTH HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; PATIENT ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ACROMEGALY; ADULT; AGED; BLOOD GLUCOSE; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 84870337017     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0361-9     Document Type: Article

References (33)

1. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119: 3189-3202
2. Holdaway IM, Rajasoorya CR, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89: 667-674
3. Moller N, Jorgensen JO, Abildgard N, Orskov L, Schmitz O, Christiansen JS (1991) Effects of growth hormone on glucose metabolism. Horm Res 36: 32-35
4. Mauras N, Haymond MW (2005) Are the metabolic effects of GH and IGF-1 separable? Growth Horm IGF Res 15: 19-27
5. Clemmons DR (2004) The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113: 25-27
6. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmonds D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94: 1509-1517
7. Strowski MZ, Blake AD (2008) Function and expression of somatostatin receptors of the endocrine pancreas. Mol Cell Endocrinol 286: 169-179
8. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico A, Valimaki M, Zgliczynski W (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87: 99-104
9. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva F, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95: 3141-3148
10. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force (2010) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl. 1): 1-68
11. Angeletti G (2003) The metabolic complications of acromegaly. J Endocrinol Invest 26(8 supp): 18-19
12. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2007) Beneficial effect on dose escalation of octreotide LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157: 579-587
13. Atttanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R (2003) Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88: 5258-5265
14. Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso L, Lombardi G, Pivonello R (2009) Glucose tolerance and somatostatin analogue treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 94: 2907-2914
15. Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso L, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94: 528-537
16. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson Chazot F, Brue T, Delemer B (2011) Diabetes in acromegaly, prevalence, risk factors and evolution; data from the French acromegaly register. Eur J Endocrinol 164: 877-884
17. DECODE Study Group (2003) Age-and-sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26: 61-69
18. Kusnik-Joinville O, Weill A, Salanave B, Ricordeau P, Allemand H (2008) Prevalence and treatment of diabetes in France. Diabetes Metab 34: 266-272
19. Abdelmalak B, Abdelmalak JB, Knittel J, Christiansen E, Mascha E, Zimmerman R, Argalius M, Foss J (2010) The prevalence of undiagnosed diabetes in non cardiac surgery patients, an observational study. Can J Anesth 57: 1058-1064
20. Kreze A, Kreze-Spirova E, Mikulecky M (2001) Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34: 1429-1433
21. Balkau B, Lange C, Fezeu L, Tichet J, Lauzon-Guillain B, Czernichow S, Fumeron F, Froguel P, Vaxillaire M, Cauchi S, Ducimetière P, Eschwege E (2008) Predicting diabetes: clinical, biological, and genetic approaches: data from the epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care 31: 2056-2061
22. Stelmachowska-Banas M, Zdunowski P, Zgliczynski W (2009) Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms? Endokrynol Pol 60: 20-24
23. Biering H, Knappe G, Gerl H, Lochs H (2000) Prevalence of diabetes in acromegaly and cushing syndrome. Acta Med Austriaca 27: 27-31
24. Nabarro JD (1987) Acromegay. Clin Endocrinol 26: 481-512
25. Holt R, Simpson H, Sönksen P (2003) The role of the growth hormone - insulin - like factor axis in glucose homeostasis. Diabet Med 20: 3-15
26. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J Clin Endocrinol Metab 94: 1500-1508
27. Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavò S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A (2011) Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164: 341-347
28. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogue treatment. Clin Endocrinol 59: 492-499
29. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M (2002) Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 25: 502-507
30. Webb S, Ortega E, Rodriguez-Espinosa J, Mato ME, Corcoy R (2001) Decreased insulin requirements after LAR-octreotide but not after lanreotide in an acromegalic patient. Pituitary 4: 275-278
31. Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J (2005) Four-year follow-up of acromegalic patients treated with the new long acting formulation of lanreotide (lanreotide Autogel). Exp Clin Endo Diabetes 113: 139-144
32. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J (2006) Effects of the long-acting somatostatin analogue lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155: 73-78
33. Ayuk J, Stewart SE, Stewart PM, Sheppard MC (2002) Longterm safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 87: 4142-4146